New hope for Parkinson's: drug infusion studied in earlier advanced patients

NCT ID NCT07227896

Not yet recruiting Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at how well the drug Foslevodopa/Foscarbidopa works for people with advanced Parkinson's disease who are still in the earlier phases of that stage. About 100 adults will receive the drug as a continuous infusion under the skin for up to 6 months. Researchers will track changes in 'off' time (when symptoms return) and quality of life through questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Foslevodopa/Foscarbidopa (a drug combination given as a continuous infusion under the skin)
What this could lead to: If successful, this could show that starting this treatment earlier in advanced Parkinson's helps reduce 'off' time and improve daily function.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It's also small (100 people) and short (6 months), so benefits may not be clear or lasting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE

Contacts and locations

Locations

Boston Medical Center Health System

Boston, Massachusetts, 02118, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.